Background Anti-interleukin (IL)-17 biological agents (BAs) have significant efficacy in the
treatment of psoriasis and psoriatic arthritis; however, adverse events (AEs) are common …

Targeting specific pathologic pro-inflammatory cytokines or related molecules leads to
excellent therapeutic effects in inflammatory arthritis, including rheumatoid arthritis …

Th17 cells play a critical role in both tissue homeostasis and inflammation during clearance
of infections as well as autoimmune and inflammatory disorders. Despite numerous efforts to …

Introduction The risk of infections associated with biological drugs (BD) and Janus kinase
inhibitors (JAKi) has been extensively explored in the literature. However, there is a dearth …

Background Psoriasis is an autoimmune skin disease associated with lipid metabolism.
Sphingosine-1-phosphate (S1P) is a bioactive lipid that plays a key role in the development …

The systemic inflammatory syndrome concept is one of the foundations that stand at the
basis of revolutionary modern and future therapies, based on the in-depth understanding of …

Interleukin (IL)-23 is a central pro-inflammatory cytokine with a broad range of effects on
immune responses. IL-23 is pathologically linked to the induction of the production of the pro …

Background: Psoriasis is an immune-mediated protracted ailment that perturbs about 100
million people globally. Anti-interleukin (IL)-23 agents have a distinctive status of safety and …

Biologic therapies have revolutionized the treatment of psoriasis. Driven by dysregulation of
the adaptive immune system, the pathogenesis of psoriasis begins with activation of …

Psoriasis is a chronic inflammatory skin disease characterized by plaque formation.
Interleukin (IL)‐23 is upregulated in psoriatic lesions and is thought to be a major regulator …